Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Vascular endothelial growth factor (VEGF) is a potent promoter of angiogenesis involved in a wide variety of physiologic processes. Intravitreal injections targeting VEGF have transformed the treatment of neovascular retinal diseases. Currently, there are four anti-VEGF agents in use: bevacizumab, ranibizumab, pegaptanib, and aflibercept. The success and frequency of anti-VEGF therapy have made the ocular safety profile of these agents of vital importance. This paper focuses on sterile endophthalmitis. In this paper, we compare the incidences of posttreatment sterile endophthalmitis among the four agents, review the mechanism of actions, and discuss the most prevalent hypotheses leading to sterile endophthalmitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fundamentally, we must acknowledge eye contains immune-privileged sites with the potential for unique immune-related responses [83].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [83]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687 · cited 3×
“VEGF165 has properties of both the diffusible and bound form of VEGF [1].”
BackgroundInfluentialRanibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Investigative Ophthalmology and Visual Science
Frey, C. (2010) · Cited by 3,350
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Ng, E. W. M., Shima, D. T., Calias, P., Cunningham, E. T., Guyer, D. R., & Adamis, A. P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1955 · Cited by 1,588
Papadopoulos, N., Martin, J., Ruan, Q., Rafique, A., Rosconi, M. P., Shi, E., Pyles, E. A., Yancopoulos, G. D., Stahl, N., & Wiegand, S. J. (2012) · Angiogenesis · doi:10.1007/s10456-011-9249-6 · Cited by 1,037
Rosenfeld, P. J., Moshfeghi, A. A., & Puliafito, C. A. (2005) · Ophthalmic Surgery, Lasers and Imaging Retina · doi:10.3928/1542-8877-20050701-14 · Cited by 904 · cited 1×
“Hindawi Publishing Corporation Mediators of Inflammation Volume 2013, Article ID 943409, 6 pages http://dx.doi.org/10.1155/2013/943409”
BackgroundInfluentialRegillo, C. D., Brown, D. M., Abraham, P., Yue, H., Ianchulev, T., Schneider, S., & Shams, N. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.10.004 · Cited by 858
FERRARA, N., DAMICO, L., SHAMS, N., LOWMAN, H., & KIM, R. (2006) · Retina · doi:10.1097/01.iae.0000242842.14624.e7 · Cited by 849
Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Wordsworth, S., & Reeves, B. C. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.04.015 · Cited by 781
Research works printed but not linked: 1
- Kay CN Tarantola RM Gehrs KM Uveitis following intravitreal bevacizumab: a non-infectious cluster Ophthalmic Surgery Lasers and Imaging 2011 42 4 292 296 2-s2.0-80052892186 21800802 · DOI · Paper page
Cited by
Aptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,221
Pharmacokinetic aspects of retinal drug delivery
del Amo, E. M., Rimpelä, A.-K., Heikkinen, E., Kari, O. K., Ramsay, E., Lajunen, T., Schmitt, M., Pelkonen, L., Bhattacharya, M., Richardson, D., et al. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.12.001 · Cited by 693
Wang, X., Fan, W., Li, N., Ma, Y., Yao, M., Wang, G., He, S., Li, W., Tan, J., Lu, Q., et al. (2023) · Genome Biology · doi:10.1186/s13059-023-02931-y · Cited by 288
“Repeated intraocular injections may lead to various adverse effects [7].”
BackgroundOcclusive Retinal Vasculitis Following Intravitreal Brolucizumab
Witkin, A. J., Hahn, P., Murray, T. G., Arevalo, J. F., Blinder, K. J., Choudhry, N., Emerson, G. G., Goldberg, R. A., Kim, S. J., Pearlman, J., et al. (2020) · Journal of VitreoRetinal Diseases · doi:10.1177/2474126420930863 · Cited by 183
“(%) White Black 24 (96) 1 (4) Location, No.”
BackgroundInfluentialErratum: Aptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.86 · Cited by 163
Baumal, C. R., Bodaghi, B., Singer, M. A., Tanzer, D. J., Seres, A., Joshi, M. R., Feltgen, N., & Gale, R. P. (2020) · Ophthalmology Retina · doi:10.1016/j.oret.2020.09.020 · Cited by 161
Self-citationAnderson, W. J., da Cruz, N. F. S., Lima, L. H., Emerson, G. G., Rodrigues, E. B., & Melo, G. B. (2021) · International Journal of Retina and Vitreous · doi:10.1186/s40942-021-00307-7 · Cited by 155
Inflammatory Complications of Intravitreal Anti-VEGF Injections
Cox, J. T., Eliott, D., & Sobrin, L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10050981 · Cited by 139
“This differs from SII and BARV, which have pain in 17 to 46% of patients [31,32,34,54,57].”
BackgroundMethodInfluentialFit for the Eye: Aptamers in Ocular Disorders
Drolet, D. W., Green, L. S., Gold, L., & Janjić, N. (2016) · Nucleic Acid Therapeutics · doi:10.1089/nat.2015.0573 · Cited by 130
Daïen, V., Nguyen, V., Essex, R. W., Morlet, N., Barthelmes, D., Gillies, M. C., Gillies, M. C., Hunt, A., Essex, R. W., Dayajeewa, C., et al. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.07.005 · Cited by 112
Zehden, J., Mortensen, X. M., Reddy, A. K., & Zhang, A. Y. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01491-y · Cited by 95
Witkin, A. J., Jaffe, G. J., Srivastava, S. K., Davis, J. L., & Kim, J. E. (2023) · Journal of VitreoRetinal Diseases · doi:10.1177/24741264231220224 · Cited by 88
Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration
Enríquez, A. B., Baumal, C. R., Crane, A. M., Witkin, A. J., Lally, D. R., Liang, M. C., Enríquez, J. R., & Eichenbaum, D. A. (2021) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.7085 · Cited by 81
Complications of Intravitreal Injections in Patients with Diabetes
Shikari, H., Silva, P. S., & Sun, J. K. (2014) · Seminars in Ophthalmology · doi:10.3109/08820538.2014.962167 · Cited by 74
“A review of vitreous inflammation associated with anti-VEGF therapy showed rates of inflammation (mild iridocyclitis to severe sterile endophthalmitis) ranging from 0.09% 1.49% with bevacizumab, 0–83% with ranibizumab, and 0–0.05% with Aflibercept.108 Although Rosenfeld109 reported a relatively high rate of iridocycli…”
BackgroundInfluentialWilliams, P. D., Chong, D., Fuller, T., & Callanan, D. (2016) · Retina · doi:10.1097/iae.0000000000000801 · Cited by 69
“or preparation of the agent.(4) The etiologies could be multifactorial based on differences in the molecules, handling, and preparation of each medication.”
BackgroundAflibercept-Related Sterile Intraocular Inflammation Outcomes
Greenberg, J. P., Belin, P., Butler, J., Feiler, D., Mueller, C., Tye, A., Friedlander, S. M., Emerson, G. G., & Ferrone, P. J. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.04.006 · Cited by 69
Souied, E. H., Dugel, P. U., Ferreira, A., Hashmonay, R., Lu, J., & Kelly, S. P. (2016) · Ophthalmic Epidemiology · doi:10.3109/09286586.2015.1090004 · Cited by 65
Gregori, N. Z., Flynn, H. W., Schwartz, S. G., Rosenfeld, P. J., Vaziri, K., Moshfeghi, A. A., Fortun, J. A., Kovach, J. L., Dubovy, S. R., Albini, T. A., et al. (2015) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20150610-08 · Cited by 69
Kiss, S., Dugel, P. U., Khanani, A. M., Broder, M. S., Chang, E. Y., Sun, G. H., & Turpcu, A. (2018) · Clinical ophthalmology · doi:10.2147/opth.s169143 · Cited by 74
Biosimilars for Retinal Diseases: An Update
Sharma, A., Kumar, N., Parachuri, N., Bandello, F. M., Kuppermann, B. D., & Loewenstein, A. (2020) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2020.11.017 · Cited by 56
Future of anti-VEGF: biosimilars and biobetters
Kapur, M., Nirula, S., & Naik, M. P. (2022) · International Journal of Retina and Vitreous · doi:10.1186/s40942-021-00343-3 · Cited by 54
Therapeutic aptamers in discovery, preclinical and clinical stages
Ismail, S. I., & Alshaer, W. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.08.006 · Cited by 54
Chakraborty, D., Maiti, A., Sheth, J. U., Boral, S. K., Mondal, S., Nandi, K., Sinha, T. K., & Das, A. (2021) · Clinical ophthalmology · doi:10.2147/opth.s328160 · Cited by 50
Brolucizumab-Associated Intraocular Inflammation in Eyes Without Retinal Vasculitis
Witkin, A. J., Hahn, P., Murray, T. G., Arévalo, J. F., Blinder, K. J., Choudhry, N., Emerson, G. G., Goldberg, R. A., Kim, S. J., Pearlman, J. A., et al. (2020) · Journal of VitreoRetinal Diseases · doi:10.1177/2474126420975303 · Cited by 44
The heroine of irregular features: physiognomy and conventions of heroine description.
Fahnestock, J. (1981) · PubMed · Cited by 37
How to schedule VEGF and PD-1 inhibitors in combination cancer therapy?
Lai, X., & Friedman, A. (2019) · BMC Systems Biology · doi:10.1186/s12918-019-0706-y · Cited by 37
Lai, X., & Friedman, A. (2018) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2018.11.018 · Cited by 37
Aflibercept high-dose (8mg) related intraocular inflammation (IOI) – a case series
Hoffmann, L., Michels, S., Eandi, C. M., Karam, M. A., Figueiredo, E. C. D. O., & Hatz, K. B. (2024) · BMC Ophthalmology · doi:10.1186/s12886-024-03788-w · Cited by 35
“Symptoms typically include blurred vision and floaters occurring 24 h to 7 days post-injection, with or without pain [9, 10].”
Complications of Intravitreous Injections in Patients with Diabetes
Gupta, A., Sun, J. K., & Silva, P. S. (2018) · Seminars in Ophthalmology · doi:10.1080/08820538.2017.1353811 · Cited by 35
“hypotheses include immune response to the antibody molecule and bacterial endotoxin contamination.(101) In a recent retrospective case series, the rates of noninfectious”
BackgroundSingh, R., Davoudi, S., & Ness, S. D. (2022) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-022-05607-8 · Cited by 36
Biotherapeutics and immunogenicity: ophthalmic perspective
Sharma, A., Kumar, N., Kuppermann, B. D., Bandello, F. M., & Loewenstein, A. (2019) · Eye · doi:10.1038/s41433-019-0434-y · Cited by 31
Vélez-Montoya, R., Sniegowski, M. C., Erlanger, M. S., & Olson, J. L. (2015) · Clinical ophthalmology · doi:10.2147/opth.s69670 · Cited by 28
Aptamer Technologies in Neuroscience, Neuro-Diagnostics and Neuro-Medicine Development
Wang, B., Kobeissy, F. H., Golpich, M., Cai, G., Li, X., Abedi, R., Haskins, W. E., Tan, W., Benner, S. A., & Wang, K. (2024) · Molecules · doi:10.3390/molecules29051124 · Cited by 31
Ophthalmic biosimilars and biologics—role of endotoxins
Sharma, A., Kumar, N., Kuppermann, B. D., Bandello, F. M., & Loewenstein, A. (2019) · Eye · doi:10.1038/s41433-019-0636-3 · Cited by 28
“used for intravitreal therapy such as bevacizumab, ranibizumab, aflibercept, and pegaptanib, with varying incidence rate [1].”
BackgroundINTRAOCULAR INFLAMMATION ASSOCIATED WITH FARICIMAB THERAPY: One-Year Real-World Outcomes
Montesel, A., Sen, S., Preston, E., Patel, P. J., Huemer, J. C., HAMILTON, R. D., Nicholson, L., Papasavvas, I., Tucker, W. R., & Yeung, I. Y. L. (2025) · Retina · doi:10.1097/iae.0000000000004394 · Cited by 25
Acute sterile endophthalmitis following intravitreal bevacizumab: case series
Vélez-Montoya, R., Ortega-Larrocea, X., Orozco‐Hernández, A., Sánchez-Bermúdez, G., Morales-Cantón, V., & García‐Aguirre, G. (2014) · Clinical ophthalmology · doi:10.2147/opth.s66230 · Cited by 25
PATEL, S. N., Storey, P. P., Pancholy, M. S., Obeid, A., Wibbelsman, T. D., Levin, H., Hsu, J., Garg, S. J., Dunn, J. P., & VANDER, J. F. (2019) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2019.06.008 · Cited by 22
WIDE-FIELD SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY
Pichi, F., Carrai, P., Bonsignore, F., Villani, E., Ciardella, A. P., & Nucci, P. (2015) · Retina · doi:10.1097/iae.0000000000000611 · Cited by 18
Kaya, M., Öner, F. H., Yağcı, B. A., Ataş, F., & Öztürk, T. (2021) · Turkish Journal of Ophthalmology · doi:10.4274/tjo.galenos.2020.84042 · Cited by 17
Sun, H., Zou, W., Zhang, Z., Huang, D., Zhao, J., Qin, B., Xie, P., Mugisha, A., Liu, Q., & Hu, Z. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.846003 · Cited by 17
“We supposed that the upregulation of TNF-α and IP-10 might contribute to the injection manipulation (Agrawal et al., 2013).”
BackgroundDolar-Szczasny, J., Bucolo, C., Zweifel, S. A., Carnevali, A., Ręjdak, R., Załuska, W., Czarnek-Chudzik, A., & Toro, M. D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.656774 · Cited by 17
Ricci, F., Calabrese, A., Felici, C. D., Missiroli, F., Pileri, M., & Regine, F. (2016) · Digital Journal of Ophthalmology · doi:10.5693/djo.01.2016.03.001 · Cited by 14
Inhibitory effect of Samul-tang on retinal neovascularization in oxygen-induced retinopathy
Lee, Y. M., Kim, C., Jo, K., Sohn, E. J., Kim, J. S., & Kim, J. (2015) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-015-0800-7 · Cited by 13
Guidance on brolucizumab management recommendations
Fonollosa, A., Gallego‐Pinazo, R., Sararols, L., Adán, A., Gálvez, M. I. L., & Figueroa, M. S. (2022) · Archivos de la Sociedad Española de Oftalmología (English Edition) · doi:10.1016/j.oftale.2022.05.006 · Cited by 14
Callanan, D., Khurana, R. N., Maturi, R. K., Patel, S. S., Wykoff, C. C., Eichenbaum, D. A., Khanani, A. M., Hassan, T., Badger, H., Mehta, S., et al. (2023) · Clinical ophthalmology · doi:10.2147/opth.s405994 · Cited by 13
Demirel, S., Bilici, S., Batıoğlu, F., & Özmert, E. (2016) · Ophthalmic Research · doi:10.1159/000444497 · Cited by 10
Hasegawa, A., Gulmezian-Sefer, M., Cheng, Y., & Srikumar, R. (2021) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-030-76367-1_9 · Cited by 15
Clinical use and future perspective of aptamers
Esawi, E., Nsairat, H., Mahmoud, I. S., Lafi, Z., Al-Kadash, A., Alragheb, B. A., Ismail, S. I., & Alhaer, W. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-85881-6.00013-0 · Cited by 10
Baiza-Durán, L. M., Sánchez‐Ríos, A., González-Barón, J., Olvera‐Montaño, O., Correa‐Gallegos, E. Y., Navarro-Sánchez, A. A., & Muñoz‐Villegas, P. (2020) · International Journal of Retina and Vitreous · doi:10.1186/s40942-020-00235-y · Cited by 9
“Due to the nature of the administration method, these findings were attributed to inflammation secondary to the intravitreal injection itself, since this is an invasive procedure and such events have been described before for this route of administration [23, 24].”
MethodAstakhov, Y. S., Belekhova, S. G., & Litvinova, E. A. (2017) · Ophthalmology Reports · doi:10.17816/ov10162-69 · Cited by 12
“Ряд публикаций показал, что после разрешения воспалительного процесса острота зрения в большинстве случаев восстанавливается до исходного уровня [3, 8, 24, 64].”
BackgroundHoffmann, L., & Hatz, K. B. (2026) · Ophthalmology and Therapy · doi:10.1007/s40123-026-01349-6 · Cited by 6
Jiang, G., Yuan, L., Liu, X., Wu, H., Yu, H., Zhang, W., Zhang, S., & Huang, Y. (2024) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2024.15 · Cited by 9
Wang, J.-K. (2015) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000168 · Cited by 6
Grewal, D. S., Schwartz, T. M., & Fekrat, S. (2017) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20170428-10 · Cited by 6
Karmacharya, M. B., Hada, B., Park, S. R., & Choi, B. H. (2018) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2017.12.004 · Cited by 5
Sterile Intraocular Inflammation After Intravitreal Injection—Diagnosis and Management
Greenberg, J. P., Peiris, T. J., & Lieberman, R. M. (2019) · Advances in Ophthalmology and Optometry · doi:10.1016/j.yaoo.2019.04.010 · Cited by 4
Gil‐Martínez, M., Rodríguez‐Cid, M. J., Fenández-Rodríguez, M. I., Blanco-Teijero, M. J., Abraldes, M. J., Bandín‐Vilar, E., Zarra‐Ferro, I., González‐Barcia, M., Gómez‐Ulla, F., & Fernández‐Ferreiro, A. (2020) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2020.01.019 · Cited by 4
Guía de recomendaciones para el manejo de brolucizumab
Fonollosa, A., Gallego‐Pinazo, R., Sararols, L., Adán, A., Gálvez, M. I. L., & Figueroa, M. S. (2022) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2022.02.006 · Cited by 5
Effects of intravitreally injected Fc fragment on rat eyes
Taubitz, T., Steinbrenner, L.-P., Tschulakow, A., Biesemeier, A., Julien, S., & Schraermeyer, U. (2016) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-016-3511-y · Cited by 4
“Nevertheless, side effects including inflammation and sterile endophthalmitis have been observed after intravitreal application of full-length antibodies [3, 4].”
BackgroundIntravitreal Anti-Vascular Endothelial Growth Factor Complications
Sergio Rojas, J. (2015) · International Journal of Ophthalmology and Clinical Research · doi:10.23937/2378-346x/1410022 · Cited by 4
Guo, S., Li, M., Jia, Z., Xu, D., Yu, C., Mei, Y., Zhao, Y., Duan, X., Guo, X., He, P., et al. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125500 · Cited by 3
Desideri, L. F., Fukuhara, P. S., Wintergerst, M. W. M., Meyer, C. H., Emerson, G. G., Anguita, R., & Melo, G. B. (2026) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2026.02.005 · Cited by 3
Ophthalmic safety profile of antiangiogenic therapy
Фурсова, А. Ж., Zabanova, V. E., Gamza, Y. A., Сергеевич, Т. М., Vasilyeva, M. A., Nikulich, I. F., & Derbeneva, A. S. (2021) · Russian Annals of Ophthalmology · doi:10.17116/oftalma2021137021114 · Cited by 3
Motohashi, R., Noma, H., Yasuda, K., Kasezawa, Y., Gotô, H., & Shimura, M. (2021) · The Open Ophthalmology Journal · doi:10.2174/1874364102115010209 · Cited by 2
Song, J. R., Park, K. H., Kang, S. W., Chin, H. S., Yu, S. Y., Park, Y.-H., Kim, Y. C., Lee, J. E., Lim, S. T., Kim, J.-G., et al. (2025) · Korean Journal of Ophthalmology · doi:10.3341/kjo.2025.0010 · Cited by 1
“While both conditions may share some clinical features they differ significantly in timing and presentation [26,27].”
Anti-VEGF safety in evolution: A comprehensive review of ocular and systemic considerations
Venkatesh, R., Biradar, P., Malwe, G., Prabhu, V., Hande, P., Kathare, R., Raj, P., Roy, R., Yadav, N., & Jayadev, C. (2026) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_3284_25 · Cited by 1
“[19] At the severe end are posterior segment–predominant reactions, including dense vitritis and retinal vasculitis, which may be occlusive and associated with capillary nonperfusion, retinal ischemia, and irreversible vision loss; recognition of occlusive retinal vasculitis as a distinct phenotype…”
InfluentialSafety Considerations of Pharmacotherapy
Stewart, M. W. (2017) · Springer eBooks · doi:10.1007/978-981-10-3509-8_9 · Cited by 1
Gil‐Martínez, M., Rodríguez‐Cid, M. J., Fenández-Rodríguez, M. I., Blanco-Teijero, M. J., Abraldes, M. J., Bandín‐Vilar, E., Zarra‐Ferro, I., González‐Barcia, M., Gómez‐Ulla, F., & Fernández‐Ferreiro, A. (2020) · Archivos de la Sociedad Española de Oftalmología (English Edition) · doi:10.1016/j.oftale.2020.01.008 · Cited by 1
Surgical and Nonsurgical Trauma
Yanoff, M., & Sassani, J. W. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-87822-7.00005-5 · Cited by 1
Complete and Early Vitrectomy for Sterile Endophthalmitis After Bevacizumab: A Case Series
Kudasiewicz-Kardaszewska, A. J., Ozimek, M. A., Kardaszewska, A., Kardaszewski, P., Kapturska, N., Jamontt, K., Bonińska, K., & Cisiecki, S. (2025) · Cureus · doi:10.7759/cureus.93996 · Cited by 1
Martínez, I. J. A. (2015) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/16735
Papel do VEGF nas alterações retinianas provocadas pela hipóxia normobárica em coelhos
Castro, V. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2017.tde-07012016-090259
Fraunfelder, F. “. T., & Fraunfelder, F. “. W. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-65375-6.00018-9
Surgical and Nonsurgical Trauma
Yanoff, M., & Sassani, J. W. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-54755-0.00005-x
Göz Hastalıklarında Güncel Çalışmalar IV
Atmaca, F., Karalezlı, A., Yaman, F., Kaderli, S. T., Pehlivanoğlu, S., Tekcan, H., Balcıoğlu, E., Özçelik, F., Alpoğan, O., Keser, S., et al. (2023) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.2538
Angiogenic Properties of Vitreous
Micera, A., Balzamino, B. O., Cosimi, P., & Cacciamani, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13820-1.00040-2
Tetsumoto, R., Matsumiya, W., Sotani, R., Kusuhara, S., & Nakamura, M. (2024) · Cureus · doi:10.7759/cureus.60356
“The sudden onset within 24 hours post-RBZ BS injection, the absence of ocular pain, and negative evidence of conjunctivitis, KPs, fibrin, and hypopyon suggested a noninfectious intraocular inflammation rather than endophthalmitis [3].”
BackgroundInfluentialFigurska, M., & Pawlik, B. A. (2025) · Lekarz Wojskowy · doi:10.53301/lw/194967
Gangwe, A. B., Jalali, S., Chattopadhyay, A., BANKER, A. S., Lahiri, K., Shah, P. K., Sharma, R. K., Das, P., Agrawal, A., Agrawal, D., et al. (2025) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2025.2572755
“In the current cohort, cases 15, 16, 18, and 19 possibly highlight this situation.”
Wang, X., Fan, W., Li, N., Ma, Y., Yao, M., Wang, G., He, S., Li, W., Tan, J., Lu, Q. C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26584143
Wang, X., Fan, W., Li, N., Ma, Y., Yao, M., Wang, G., He, S., Li, W., Tan, J., Lu, Q. C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26584134
Wang, X., Fan, W., Li, N., Ma, Y., Yao, M., Wang, G., He, S., Li, W., Tan, J., Lu, Q. C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26584146
Wang, X., Fan, W., Li, N., Ma, Y., Yao, M., Wang, G., He, S., Li, W., Tan, J., Lu, Q., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26584140
Wang, X., Fan, W., Li, N., Ma, Y., Yao, M., Wang, G., He, S., Li, W., Tan, J., Lu, Q. C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26584137
Ma, M., & Shen, J. (2026) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-026-07144-0
“For example, patients may develop resistance to these drugs over time, and repeated intraocular injections can lead to various adverse effects [ 119, 120].”
Engineered RPE Cell Therapy for Controllable Anti-VEGF Delivery in Neovascular AMDPreprint
Hacibekiroglu, S., Mitrousis, N., Jong, E., Michael, I., Yang, H., Massumi, M., Li, B., Harding, J., Vawda, R., van der Kooy, D., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10021402/v1
Metadata
- Authors
- Agrawal, S., Joshi, M., & Christoforidis, J. B.
- Affiliations
- Banner - University Medical Center Tucson (US)
- Corresponding author
- Christoforidis, John B.
- Venue
- Mediators of Inflammation
- Publisher
- Wiley
- Published
- 2013
- Volume
- 2013
- Pages
- 1-6
- ISSN
- 0962-9351 (ISSN-L)
- 1466-1861
- PMC
- PMC3836427
- OpenAlex
- W2022562553
- Cited by
- 83
- References
- 55
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 11 · 2023: 5 · 2022: 6 · 2021: 9 · 2020: 8 · 2019: 7 · 2018: 5 · 2017: 5 · 2016: 7 · 2015: 8 · 2014: 2
- FWCI
- 0.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Mediators of Inflammation (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- vitreous inflammation, sterile endophthalmitis, anti-VEGF therapy, intravitreal injection, bevacizumab, ranibizumab, pegaptanib, aflibercept, vascular endothelial growth factor, eye safety, pathogenesis
- MeSH terms
- Bevacizumab, Ranibizumab, Humans, Infant, Newborn, Inflammation, Endophthalmitis, Recombinant Fusion Proteins, Retinal Diseases, Risk, Vitreous Body, Angiogenesis Inhibitors, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor A, Aptamers, Nucleotide, Intravitreal Injections, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.